Please use this identifier to cite or link to this item: https://doi.org/10.3389/fphar.2021.828856
DC FieldValue
dc.titleRepurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
dc.contributor.authorMa, Z
dc.contributor.authorWoon, CYN
dc.contributor.authorLiu, CG
dc.contributor.authorCheng, JT
dc.contributor.authorYou, M
dc.contributor.authorSethi, G
dc.contributor.authorWong, ALA
dc.contributor.authorHo, PCL
dc.contributor.authorZhang, D
dc.contributor.authorOng, P
dc.contributor.authorWang, L
dc.contributor.authorGoh, BC
dc.date.accessioned2022-06-09T07:43:01Z
dc.date.available2022-06-09T07:43:01Z
dc.date.issued2021-12-31
dc.identifier.citationMa, Z, Woon, CYN, Liu, CG, Cheng, JT, You, M, Sethi, G, Wong, ALA, Ho, PCL, Zhang, D, Ong, P, Wang, L, Goh, BC (2021-12-31). Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?. Frontiers in Pharmacology 12 : 828856-. ScholarBank@NUS Repository. https://doi.org/10.3389/fphar.2021.828856
dc.identifier.issn1663-9812
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/226873
dc.description.abstractCancer has become a global health problem, accounting for one out of six deaths. Despite the recent advances in cancer therapy, there is still an ever-growing need for readily accessible new therapies. The process of drug discovery and development is arduous and takes many years, and while it is ongoing, the time for the current lead compounds to reach clinical trial phase is very long. Drug repurposing has recently gained significant attention as it expedites the process of discovering new entities for anticancer therapy. One such potential candidate is the antimalarial drug, artemisinin that has shown anticancer activities in vitro and in vivo. In this review, major molecular and cellular mechanisms underlying the anticancer effect of artemisinin and its derivatives are summarised. Furthermore, major mechanisms of action and some key signaling pathways of this group of compounds have been reviewed to explore potential targets that contribute to the proliferation and metastasis of tumor cells. Despite its established profile in malaria treatment, pharmacokinetic properties, anticancer potency, and current formulations that hinder the clinical translation of artemisinin as an anticancer agent, have been discussed. Finally, potential solutions or new strategies are identified to overcome the bottlenecks in repurposing artemisinin-type compounds as anticancer drugs.
dc.publisherFrontiers Media SA
dc.sourceElements
dc.subjectanticancer therapy
dc.subjectartemisinin
dc.subjectartemisinin derivatives
dc.subjectdrug repurposing
dc.subjectpharmacokinetics
dc.subjectsignalling pathways
dc.typeReview
dc.date.updated2022-06-07T06:55:25Z
dc.contributor.departmentDEPT OF PHARMACOLOGY
dc.contributor.departmentDEPT OF MEDICINE
dc.contributor.departmentPHARMACY
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.3389/fphar.2021.828856
dc.description.sourcetitleFrontiers in Pharmacology
dc.description.volume12
dc.description.page828856-
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Repurposing Artemisinin and its Derivatives as Anticancer Drugs A Chance or Challenge.pdf1.89 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

42
checked on Nov 17, 2022

Download(s)

1
checked on Nov 17, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.